Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18911062 | 0.85 | LMNA (0.50) | LMNATSHRCA1CA2HTT | |
| SCHEMBL9607168 | 0.83 | LMNA (0.69) | LMNAKMT2ATRPA1SMN1; SMN2 | |
| SCHEMBL6190389 | 0.83 | LMNA (0.58) | LMNAHTTSMN1; SMN2 | |
| SCHEMBL7399740 | 0.83 | TSHR (0.65) | LMNATSHRCA1CA2CA7 | |
| SCHEMBL18905358 | 0.82 | LMNA (0.47) | LMNATSHRCA1CA2HTT | |
| SCHEMBL22785967 | 0.81 | CA1 (0.50) | LMNATSHRCA1CA2CA7 | |
| SCHEMBL11696497 | 0.81 | LMNA (0.56) | LMNAHTT | |
| SCHEMBL10178438 | 0.80 | TSHR (0.56) | TSHRTACR1NPC1ALDH1A1 | |
| Isopropyl Alcohol SCHEMBL29076646 | 0.78 | TSHR (0.71) | LMNATSHRCA1CA2CA7 | |
| Phenylpropanol SCHEMBL56673 | 0.78 | LMNA (1.00) | LMNATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425513-A1 | OXAZOLE, OXADIAZOLE, AND INDOLE DERIVATIVES FOR THE INHIBITION OF USP28 | CARMOT THERAPEUTICS, INC. | 2024-12-26 | — | — | US | disclosed |
| EP-4419508-A2 | OXAZOLE, OXADIAZOLE, AND INDOLE DERIVATIVES FOR THE INHIBITION OF USP28 | Carmot Therapeutics, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-118302414-A | Oxazole, oxadiazole and indole derivatives useful for inhibiting USP28 | 卡莫特医疗有限公司 | 2024-07-05 | — | — | CN | disclosed |
| WO-2023069721-A2 | OXAZOLE, OXADIAZOLE, AND INDOLE DERIVATIVES FOR THE INHIBITION OF USP28 | CARMOT THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023069721-A2 | OXAZOLE, OXADIAZOLE, AND INDOLE DERIVATIVES FOR THE INHIBITION OF USP28 | CARMOT THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425513-A1 | OXAZOLE, OXADIAZOLE, AND INDOLE DERIVATIVES FOR THE INHIBITION OF USP28 | USP28, USP25, USP39 | LMNA 4221/4885TSHR 3475/4885CA1 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.